GO:2000486 negative regulation of glutamine transport: Metabolic Signaling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000486 describes any process that stops, prevents, or reduces the frequency, rate, or extent of glutamine transport.
• Glutamine transport is mediated by SLC family transporters such as SLC38A3 and SLC38A5, and its negative regulation impacts cancer metabolism, immune function, and hepatic physiology [2,7].
• Negative regulation can occur through signaling pathways like MAPK-regulated 4F2hc/Girdin complex, which suppresses amino acid signaling.
• Dysregulation of glutamine transport is linked to pancreatic cancer gemcitabine resistance, breast cancer metastasis, and hepatocellular carcinoma [2,3,7].
• CRISPR knockout, point mutation, and overexpression models are essential to dissect causal roles of transporters and regulators in glutamine transport [2,7].
• Studying GO:2000486 requires integrated methods such as metabolic flux analysis, RNA-seq, and proteomics to capture dynamic regulation [1,5].
Description
Glutamine is the most abundant amino acid in circulation and serves as a critical fuel for rapidly proliferating cells, including cancer cells and activated immune cells [1,4]. The transport of glutamine across cellular membranes is mediated by a suite of solute carrier (SLC) transporters, and its dysregulation is associated with metabolic reprogramming in diseases such as cancer and diabetes [2,7]. The Gene Ontology term GO:2000486, negative regulation of glutamine transport, captures the biological processes that attenuate this transport activity. Understanding this term is vital for researchers aiming to manipulate glutamine metabolism for therapeutic benefit, as it encompasses diverse mechanisms from transcriptional repression to post-translational modification of transporters [5,8]. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a comprehensive overview of the genes, functions, and research methods relevant to GO:2000486.
negative regulation of glutamine transport At A Glance
| GO ID | GO:2000486 |
|---|---|
| GO term | negative regulation of glutamine transport |
| Ontology | biological_process |
| Synonym | negative regulation of L-glutamine transport |
| Major function | Attenuation of glutamine transport across cellular membranes |
| Related transporters | SLC38A3, SLC38A5, SLC1A5, SLC7A5 |
| Key signaling regulators | MAPK, Girdin, 4F2hc, miR-122 |
| Disease relevance | Cancer metabolism, metastasis, chemoresistance, hepatic disorders |
What Is GO:2000486?
GO:2000486, negative regulation of glutamine transport, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of glutamine transport. This biological process can act on the transport of L-glutamine, the predominant form of glutamine in biological systems, and may involve direct inhibition of transporter activity, downregulation of transporter expression, or interference with signaling pathways that promote transport.
Why Is negative regulation of glutamine transport Important in Cell Biology?
Negative regulation of glutamine transport is crucial for maintaining metabolic homeostasis and preventing excessive nutrient uptake that can fuel pathological cell growth. In cancer, upregulated glutamine transport supports anabolic metabolism, and its negative regulation can suppress tumor progression or sensitize cells to therapy [2,7]. In immune cells, glutamine transport must be tightly controlled to balance effector functions and avoid exhaustion. Moreover, hepatic glutamine metabolism is regulated by microRNAs such as miR-122, highlighting the importance of negative regulation in liver physiology. Thus, understanding GO:2000486 provides insights into fundamental metabolic control and offers targets for therapeutic intervention.
• Regulates cellular glutamine availability for biosynthetic pathways and energy production.
• Modulates cancer cell sensitivity to chemotherapy, as shown for SLC38A5 in pancreatic cancer.
• Influences immune cell function, including CD8+ T cell antitumor immunity via glycolytic metabolism.
• Controls hepatic glutamine metabolism through miR-122, impacting liver disease.
• Affects skeletal muscle glutamine turnover, relevant to muscle wasting conditions.
• Involved in amino acid signaling cross-talk via MAPK-regulated 4F2hc/Girdin complex.
• Potential target for overcoming gemcitabine resistance in pancreatic cancer.
• Linked to breast cancer metastasis through SLC38A3 and Gsk3β/β-catenin/EMT pathway.
• May influence hepatocellular carcinoma sensitivity to OXPHOS inhibition via DYRK1A-TGF-β axis.
• Provides a framework for studying transporter regulation in metabolic diseases.
What Happens During negative regulation of glutamine transport?
Transcriptional and Post-transcriptional Control
In simple terms: Cells can reduce the number of glutamine transporters by making less mRNA or destroying it faster.
Negative regulation of glutamine transport often begins with reduced expression of transporter genes. For example, miR-122 negatively regulates hepatic glutamine metabolism by targeting components of the transport machinery, leading to decreased glutamine uptake. Similarly, transcriptional repression of SLC38A3 or SLC38A5 can limit glutamine influx, as observed in breast cancer and pancreatic cancer models [2,7].
Post-translational Modification of Transporters
In simple terms: Existing transporter proteins can be modified to make them less active or to remove them from the cell surface.
Transporters can be phosphorylated, ubiquitinated, or otherwise modified to reduce their activity or promote their degradation. The MAPK-regulated 4F2hc/Girdin complex negatively regulates amino acid signaling, which may involve post-translational inhibition of glutamine transporters. Such modifications rapidly adjust transport rates in response to extracellular cues.
Signaling Pathways That Suppress Transport
In simple terms: Signals from outside the cell can activate pathways that shut down glutamine uptake.
The MAPK pathway, through the 4F2hc/Girdin complex, acts as a negative regulator of amino acid signaling, indirectly reducing glutamine transport. Additionally, the DYRK1A-TGF-β signaling axis has been implicated in determining sensitivity to OXPHOS inhibition in hepatocellular carcinoma, potentially through modulation of glutamine metabolism. These pathways integrate growth factor signals with metabolic transport.
Metabolic Feedback and Transport Inhibition
In simple terms: High levels of glutamine or its metabolites can feed back to block further transport.
Intracellular glutamine levels can feedback to inhibit transport activity, preventing excessive accumulation. In Escherichia coli, glutamine transport is regulated in response to nutrient availability. In mammalian cells, such feedback may involve mTOR signaling, although direct evidence for glutamine transport negative regulation via mTOR is limited in the provided citations.
Regulation of Glutamine Turnover in Muscle
In simple terms: In muscle, the balance between glutamine release and uptake is controlled to maintain nitrogen balance.
Skeletal muscle glutamine turnover is regulated by membrane transport, and negative regulation can occur under conditions of stress or disease. This ensures that glutamine is available for other tissues like the liver and immune system.
Key Genes Involved in GO:2000486 negative regulation of glutamine transport
The following genes and proteins are central to the negative regulation of glutamine transport, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC38A3 | Glutamine transporter; promotes metastasis | Breast cancer metastasis via Gsk3β/β-catenin/EMT |
| SLC38A5 | Glutamine transporter; modulates ferroptosis | Gemcitabine resistance in pancreatic cancer |
| SLC1A5 | Neutral amino acid transporter; glutamine uptake | Cancer metabolism, immune function |
| SLC7A5 | L-type amino acid transporter; glutamine efflux | mTOR signaling, cancer growth |
| GAPDH | Glycolytic enzyme; serotonylation couples to metabolism | CD8+ T cell antitumor immunity |
| DYRK1A | Kinase; regulates TGF-β signaling | HCC sensitivity to OXPHOS inhibition |
| miR-122 | MicroRNA; regulates hepatic glutamine metabolism | Liver metabolism and disease |
| 4F2hc (SLC3A2) | Chaperone for amino acid transporters | MAPK-regulated amino acid signaling |
| Girdin | Scaffold protein; interacts with 4F2hc | Negative regulation of amino acid signaling |
| MAPK | Signaling kinase; regulates 4F2hc/Girdin | Amino acid signaling suppression |
| GSK3β | Kinase; involved in EMT | Breast cancer metastasis |
| β-catenin | Transcription co-activator; EMT regulator | Breast cancer metastasis |
| TGF-β | Cytokine; signaling in HCC | OXPHOS inhibition sensitivity |
| SLC38A1 | Glutamine transporter | Cancer metabolism |
| SLC38A2 | Glutamine transporter | Cancer metabolism |
| SLC6A14 | Amino acid transporter | Cancer metabolism |
| ASCT2 | Glutamine transporter | Cancer metabolism |
How Is negative regulation of glutamine transport Regulated?
Negative regulation of glutamine transport is itself regulated by diverse mechanisms. The MAPK pathway, through the 4F2hc/Girdin complex, suppresses amino acid signaling, thereby negatively regulating glutamine transport. MicroRNAs such as miR-122 downregulate hepatic glutamine metabolism, including transport components. Additionally, the DYRK1A-TGF-β signaling axis may influence glutamine transport in hepatocellular carcinoma. In bacteria, glutamine transport is regulated in response to nitrogen availability. These layers of regulation ensure that glutamine uptake is tightly coupled to cellular needs.
negative regulation of glutamine transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC38A5 | Pancreatic cancer gemcitabine resistance | Knockout in pancreatic cancer cell lines |
| SLC38A3 | Breast cancer metastasis | Knockout or overexpression in breast cancer cells |
| DYRK1A | Hepatocellular carcinoma OXPHOS sensitivity | Point mutation or knockout in HCC cells |
| miR-122 | Hepatic glutamine metabolism | Knockout or overexpression in hepatocytes |
| GAPDH | CD8+ T cell antitumor immunity | Knock-in of serotonylation site in T cells |
Cancer Metabolism and Chemoresistance
Dysregulated glutamine transport is a hallmark of cancer. SLC38A5 modulates ferroptosis and contributes to gemcitabine resistance in pancreatic cancer, and its negative regulation could restore chemosensitivity. SLC38A3 promotes breast cancer metastasis via the Gsk3β/β-catenin/EMT pathway, suggesting that inhibiting this transporter may reduce metastasis. In hepatocellular carcinoma, the DYRK1A-TGF-β axis determines sensitivity to OXPHOS inhibition, potentially through glutamine transport regulation.
Immune Cell Function
Glutamine metabolism is critical for CD8+ T cell antitumor immunity. A GAPDH serotonylation system couples glycolytic metabolism to antitumor immunity, and negative regulation of glutamine transport may impact this process by limiting glutamine availability.
Hepatic and Metabolic Disorders
miR-122 regulates hepatic glutamine metabolism, and its dysregulation is associated with liver disease. Negative regulation of glutamine transport in the liver is essential for nitrogen balance and may be impaired in metabolic disorders.
Muscle Wasting and Skeletal Muscle Turnover
Skeletal muscle glutamine turnover is regulated by membrane transport, and negative regulation is important for maintaining muscle mass during catabolic states.
From negative regulation of glutamine transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC38A5 negatively regulate glutamine transport? | CRISPR knockout in pancreatic cancer cells |
| What is the role of SLC38A3 in breast cancer metastasis? | Knockout and overexpression in breast cancer cell lines |
| How does DYRK1A mutation affect glutamine transport? | Point mutation knock-in in HCC cells |
| Does miR-122 target glutamine transporters? | Knockout of miR-122 in hepatocytes |
| Can GAPDH serotonylation modulate glutamine transport? | Knock-in of serotonylation-deficient GAPDH |
| What is the effect of 4F2hc/Girdin complex on transport? | Overexpression of Girdin mutants |
How to Study the negative regulation of glutamine transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| 13C-glutamine flux analysis | Glutamine uptake and metabolic fate | Cancer metabolism studies |
| RNA-seq | Transporter gene expression | Identifying negative regulators |
| Phosphoproteomics | Post-translational modifications | Signaling pathways |
| Glutamine uptake assay | Transport rate | Functional validation |
| CRISPR knockout | Gene function | Causal role of transporters |
| Overexpression | Gain-of-function | Regulator studies |
| Immunoblotting | Protein levels | Transporter expression |
| Metabolomics | Metabolite levels | Pathway impact |
Metabolic Flux Analysis
Metabolic flux analysis using labeled glutamine (e.g., 13C-glutamine) allows direct measurement of transport rates and pathway activity. This method is essential to quantify the impact of negative regulators on glutamine uptake and metabolism [1,4].
RNA-seq and Transcriptomics
RNA sequencing can identify changes in transporter gene expression upon negative regulation. For example, miR-122 knockout alters hepatic glutamine metabolism genes. Transcriptomics also reveals signaling pathways involved in transport suppression.
Proteomics and Post-translational Modification Analysis
Proteomics can detect changes in transporter protein abundance and modifications. The MAPK-regulated 4F2hc/Girdin complex involves phosphorylation events that can be studied by phosphoproteomics.
Imaging and Transport Assays
Fluorescent glutamine analogs or radiolabeled glutamine uptake assays measure transport activity in live cells. These are used to validate negative regulation in knockout or overexpression models [2,7].
How CRISPR Can Be Used to Study GO:2000486 negative regulation of glutamine transport
Knockout
CRISPR knockout of glutamine transporters such as SLC38A5 or SLC38A3 can abolish transport activity, revealing their role in negative regulation. For example, SLC38A5 knockout sensitizes pancreatic cancer cells to gemcitabine, demonstrating its function in chemoresistance. Knockout of SLC38A3 reduces breast cancer metastasis.
Point Mutation
Point mutations can dissect specific residues required for transporter regulation. For instance, mutating phosphorylation sites in 4F2hc or Girdin can prevent negative regulation of amino acid signaling. DYRK1A point mutations may alter its kinase activity and downstream effects on glutamine transport.
Knock-in
Knock-in of tagged transporters or reporters allows visualization and tracking of glutamine transport in live cells. This can be used to study dynamic regulation and localization of transporters like SLC38A3.
Overexpression
Overexpression of negative regulators such as Girdin or miR-122 can suppress glutamine transport, providing gain-of-function evidence. Overexpression of SLC38A5, conversely, increases transport and resistance to ferroptosis.
How EDITGENE Supports negative regulation of glutamine transport Research
Researchers studying negative regulation of glutamine transport-related genes often need to determine whether a candidate gene is causally involved in transport suppression or whether it is merely correlated with metabolic changes. This requires precise genetic models that can knockout, mutate, or overexpress the gene of interest in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of glutamine transport research.
Frequently Asked Questions About negative regulation of glutamine transport
What is GO:2000486?
GO:2000486 is a Gene Ontology term for negative regulation of glutamine transport, describing any process that stops, prevents, or reduces the frequency, rate, or extent of glutamine transport.
What genes are involved in negative regulation of glutamine transport?
Key genes include SLC38A3, SLC38A5, SLC1A5, SLC7A5, GAPDH, DYRK1A, miR-122, 4F2hc, Girdin, and MAPK, as supported by recent literature [1,2,3,5,7,8].
How is glutamine transport negatively regulated in cancer?
In cancer, negative regulation can occur through reduced expression of transporters like SLC38A5 or SLC38A3, or via signaling pathways such as MAPK-regulated 4F2hc/Girdin complex [2,7,8].
What diseases are associated with dysregulated glutamine transport?
Dysregulated glutamine transport is linked to pancreatic cancer chemoresistance, breast cancer metastasis, hepatocellular carcinoma, and hepatic metabolic disorders [2,3,5,7].
What methods are used to study negative regulation of glutamine transport?
Common methods include CRISPR knockout, metabolic flux analysis, RNA-seq, proteomics, and glutamine uptake assays [1,2,5,8].
Can CRISPR be used to study negative regulation of glutamine transport?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of genes in glutamine transport regulation [2,7].
What is the role of SLC38A5 in glutamine transport?
SLC38A5 is a glutamine transporter that modulates ferroptosis and contributes to gemcitabine resistance in pancreatic cancer; its negative regulation could enhance chemosensitivity.
How does miR-122 regulate glutamine metabolism?
miR-122 negatively regulates hepatic glutamine metabolism, including transport components, thereby controlling liver glutamine homeostasis.
What is the significance of 4F2hc/Girdin complex in glutamine transport?
The MAPK-regulated 4F2hc/Girdin complex negatively regulates amino acid signaling, which indirectly suppresses glutamine transport.
Why is negative regulation of glutamine transport important for immune cells?
Glutamine transport supports CD8+ T cell antitumor immunity, and its negative regulation may impact T cell function and metabolic fitness.
Conclusion
GO:2000486, negative regulation of glutamine transport, is a critical biological process that controls glutamine availability for cellular metabolism. Its dysregulation is implicated in cancer progression, chemoresistance, and metabolic disorders. Understanding the genes and mechanisms involved, such as SLC38A5, SLC38A3, miR-122, and the 4F2hc/Girdin complex, provides opportunities for therapeutic intervention. Advanced CRISPR models and multi-omics approaches are essential to unravel the complexities of this regulation and translate findings into clinical applications.
References
- 1. Wang X et al.. 2024. A GAPDH serotonylation system couples CD8(+) T cell glycolytic metabolism to antitumor immunity.. Mol Cell 84(4):760-775.e7 PMID: 38215751
- 2. Kim MJ et al.. 2023. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.. Cells 12(20) PMID: 37887353
- 3. Cao Y et al.. 2025. DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.. Dev Cell 60(10):1483-1497.e7 PMID: 39798576
- 4. Hundal HS. 1991. Role of membrane transport in the regulation of skeletal muscle glutamine turnover.. Clin Nutr 10 Suppl:33-42 PMID: 16839953
- 5. Sengupta D et al.. 2020. Regulation of hepatic glutamine metabolism by miR-122.. Mol Metab 34:174-186 PMID: 32180557
- 6. Willis RC et al.. 1975. Regulation of Glutamine Transport in Escherichia coli.. J Bacteriol 122(3):1032-7 PMID: 238938
- 7. Tan Z et al.. 2024. Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3β/β-catenin/EMT pathway.. Cancer Lett 586:216653 PMID: 38309615
- 8. Weng L et al.. 2018. Negative regulation of amino acid signaling by MAPK-regulated 4F2hc/Girdin complex.. PLoS Biol 16(3):e2005090 PMID: 29538402
